EP3661484A1 — Formulations comprising a nucleic acid in a high concentration
Assigned to Jazz Pharmaceuticals Ireland Ltd · Expires 2020-06-10 · 6y expired
What this patent protects
In accordance with the present invention, high concentration, low viscosity nucleic acid compositions, which can be administered by multiple parenteral routes, may allow less frequent dosing than currently available nucleic acid products. In particular, low viscosity defibrotide …
USPTO Abstract
In accordance with the present invention, high concentration, low viscosity nucleic acid compositions, which can be administered by multiple parenteral routes, may allow less frequent dosing than currently available nucleic acid products. In particular, low viscosity defibrotide formulations for subcutaneous, intramuscular and intraperitoneal administration are more convenient for the patient and / or may be administered outside the hospital setting. The formulations of the invention can be used for the treatment of numerous conditions including, for example, the treatment of peripheral arterial diseases, treatment of acute renal failure, treatment of acute myocardial ischemia, and treatment and prevention. sinusoidal obstruction syndrome, or veno-occlusive disease.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.